CD130/gp130 antibody

Catalog No. ABIN1383680

There is 1 publication for this product available. The Mouse Monoclonal anti-CD130/gp130 antibody is suitable to detect CD130/gp130 in samples from Human. It has been validated for IHC and FACS.

Quick Overview for CD130/gp130 antibody (ABIN1383680)

Target: CD130/gp130 (IL6ST) (Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor) (IL6ST))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD130/gp130 antibody is un-conjugated

Application: Immunohistochemistry (IHC), Flow Cytometry (FACS)

Clone: B-R3

Product Details anti-CD130/gp130 Antibody

Specificity: Recognises Gp130, common subunit for IL-6, IL-11, OSM, LIF, CNTF, CT-1 receptors, a 130-140 kDa protein

Purification: Ion exchange chromatography

Immunogen: Natural soluble gp130,Myeloma X63/AG.8653 x Balb/c spleen cells

Isotype: IgG2a, kappa

Application Details

Application Notes: Use 10 μL to label 10^6 cells or 100 μL of whole blood

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Phosphate-buffered saline with 1 % BSA and 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Stable at +2-8°C for 12 months. For longer storage freeze aliquots.

References for anti-CD130/gp130 antibody (ABIN1383680)

Kurth, Horsten, Pflanz, Timmermann, Küster, Dahmen, Tacken, Heinrich, Müller-Newen: "Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 164, Issue 1, pp. 273-82, (2000) (PubMed).

Target Details for CD130/gp130

Target: CD130/gp130 (IL6ST) (Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor) (IL6ST))

Alternative Name: CD130

Background: Gp130

Molecular Weight: 130-140 kDa

Pathways: JAK-STAT Signaling, Cellular Glucan Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Cancer Immune Checkpoints